Compare Alcon AG (ALC) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs ProShares UltraPro S&P500 — how do they compare? Alcon AG trades at $66.79 (market cap $32.69B), while ProShares UltraPro S&P500 trades at $140.25. The key difference: Alcon AG pays a 0.54% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | UPRO | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $150.93 |
52-Week Low | $62.02 | $89.29 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
UPRO, the ProShares UltraPro S&P 500 ETF, trades at $144.41, up 2.64% with a bullish technical outlook from moving averages. The leveraged ETF faces neutral sentiment from oscillators while tracking S&P 500 performance. Recent news highlights sector rotation from tech stocks and mixed analyst views on S&P 500 targets ranging from 8,000 to 8,800 by year-end 2026.
The leveraged structure amplifies both gains and losses, making UPRO suitable for short-term trading amid expected S&P 500 volatility. Key risks include Fed policy uncertainty and sector rotation pressures, while opportunities exist if the S&P 500 reaches analyst targets. Earnings season performance and AI sector momentum remain critical catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
